Abeona Therapeutics

Abeona Therapeutics

Abeona Therapeutics

Abeona is developing therapies for children with rare lysosomal diseases for the deadly childhood diseases Sanfilippo (SF) Syndrome Type A and TypeB.
Type
B2c
Raised
$104.9M
Follow us
Alexa global traffic share
Latest funding Show all
$92,000,000
Post-IPO equity - 2017
$8,500,000
Venture capital - 2015
George Soros
Team Size
1–10
Employees

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when Abeona Therapeutics makes some noise.